Doctor On Demand said the move improves access to high-quality, convenient healthcare for beneficiaries across all 50 states.
Through Doctor On Demand, beneficiaries are able to connect with a board-certified physician of their choice over secure live video from home, 24 hours a day, 7 days a week.
Doctor On Demand is the first nationwide, full-service telehealth provider to expand its medical services to include Medicare Part B coverage following the Centers for Medicare and Medicaid Services expansion of telehealth services in response to the COVID-19 outbreak.
The Medicare Part B population consists largely of Americans over the age of 65, many of whom are considered at heightened risk during the pandemic.
Beneficiaries can access consistent medical care for 90 % of the most common conditions treated by both primary care and urgent care facilities, including diagnosis and testing of COVID-19; typical ailments like infections, rashes, cold and flu; ongoing care of chronic disease like asthma and COPD, diabetes, high blood pressure, high cholesterol and thyroid issues; and for prescription refills.
Patients can see the same physician time and time again, building a trusted, personal relationship via video.
Prior to CMS's expansion of telemedicine to those with Medicare Part B coverage, Doctor On Demand had already seen rapid adoption of its virtual care services within this demographic, with patient registrations for the 65 and over age group growing by nearly 150 % in March.
Doctor On Demand can be accessed through a smartphone, tablet or computer by downloading the Doctor On Demand app from the App Store or Google Play, or from a web browser.
To register, beneficiaries enter a valid email address, Medicare ID number, and a phone number.
During the COVID-19 public health emergency, Doctor On Demand is waiving the copay for Medicare Part B beneficiaries, as permitted by government policy.
The company is headquartered in San Francisco with offices in Minneapolis and Washington, DC.
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults